Park Square is pleased to announce the placement of Robert Gallotto as President and Chief Executive Officer at Synspira Therapeutics.
Synspira Therapeutics today announced the appointment of Robert Gallotto as President and Chief Executive Officer; he will also join the Board of Directors. Mr. Gallotto will succeed Shenda Baker, Ph.D., who served as interim Chief Executive Officer. Synspira is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis and other rare diseases. Its lead product, SNSP113, targets the key drivers of pulmonary decline in cystic fibrosis and other progressive pulmonary diseases, including life-threatening pulmonary infections.